Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Implantica

52,30 SEK

-0,95 %

Mindre end 1K følgere

IMP A SDB

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
-0,95 %
+4,70 %
-11,80 %
+21,91 %
+52,03 %
+52,92 %
+24,97 %
-53,68 %
-45,84 %

Implantica operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes implantable medical instruments, which are also used for the treatment of diseases affecting the esophagus. In addition to the main business, related ancillary services are offered, particularly focused on eHealth. The business is operated globally with the largest presence in North America and Europe.

Læs mere
Markedsværdi
61,88 mia. SEK
Aktieomsætning
1,72 mio. SEK
Omsætning
22,25 mio.
EBIT %
-1.312,89 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
25.2
2026

Årsrapport '25

Alle
Selskabspræsentationer
Selskabsmeddelelser
ViserAlle indholdstyper
Pressemeddelelse25.11.2025, 07.00

Implantica: RefluxStop® "Best in Class" at Japan Foregut Conference as 5-Year Data and Extensive Safety Cohort is Presented to 120 Leading Surgeons

Implantica
Pressemeddelelse11.11.2025, 07.00

Implantica: RefluxStop® takes center stage at 2025 European Foregut Society meeting

Implantica
Implantica, Webcast, Q3'25
Videopræsentation31.10.2025, 14.00

Implantica, Webcast, Q3'25

Implantica

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse31.10.2025, 07.00

Implantica publishes Interim Report January - September 2025 (Q3)

Implantica
Pressemeddelelse27.10.2025, 08.30

Implantica presents the third quarter 2025 on October 31 at 15:00 CET

Implantica
Pressemeddelelse13.10.2025, 08.30

Implantica completes FDA 100-Day Meeting for RefluxStop® PMA application

Implantica
Pressemeddelelse6.10.2025, 06.00

Implantica Successfully Completes MDSAP Recertification Audit

Implantica
Pressemeddelelse25.9.2025, 06.00

Implantica steps up to close the treatment gap with RefluxStop® as main device competitor exits Europe and the UK

Implantica
Pressemeddelelse24.9.2025, 06.00

Implantica announces U.S. FDA has provided feedback on the final RefluxStop® PMA submission, Module 3

Implantica
Pressemeddelelse17.9.2025, 06.00

Implantica's RefluxStop® sparks strong excitement at the American Foregut Society meeting, ahead of pending US FDA approval

Implantica
Selskabsmeddelelse10.9.2025, 19.00

Implantica announces the payment of share rewards based on the AGM approved share-based incentive program as a directed share issue of own shares of the company without consideration

Implantica
Pressemeddelelse10.9.2025, 06.00

Implantica ramps-up production with 10,000 RefluxStop® units in preparation for U.S. launch, pending FDA PMA approval

Implantica
Implantica, Audiocast, Q2'25
Videopræsentation14.8.2025, 13.00

Implantica, Audiocast, Q2'25

Implantica
Selskabsmeddelelse14.8.2025, 06.00

Implantica publishes Interim Report January - June 2025 (Q2)

Implantica
Pressemeddelelse13.8.2025, 06.00

Implantica finishes new multi-cavity production tool for RefluxStop® to support manufacturing ramp-up in the U.S. pending FDA approval

Implantica
Pressemeddelelse7.8.2025, 11.05

Implantica presents the second quarter 2025 on August 14 at 15:00 CEST

Implantica
Pressemeddelelse7.8.2025, 06.00

Implantica announces second publication of groundbreaking 5-year results from the landmark RefluxStop® clinical study

Implantica
Pressemeddelelse1.7.2025, 06.00

Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success

Implantica
Pressemeddelelse24.6.2025, 06.00

Implantica submits the last and final module 3 of the FDA PMA Application for RefluxStop® for US market approval

Implantica
Pressemeddelelse17.6.2025, 06.00

Implantica announces successful UK RefluxStop™ Users Meeting addressing growing demand after the final and positive UK NICE recommendations on use of RefluxStop in NHS public hospitals

Implantica
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.